
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp is poised for positive growth driven by several key factors, including an anticipated increase in iDose revenue estimates by 3.5% to 5.9% from FY26 onward due to a rising proportion of repeat administration patients. The company's expanding total addressable market (TAM) through upcoming launches and its pipeline of innovative products suggests significant potential for revenue growth and a path towards profitability in the coming years. Furthermore, Glaukos has demonstrated mid-single digit revenue growth in domestic non-iDose glaucoma products, indicating a solid performance that aligns with broader market trends, and management has highlighted international strength as a promising area for expansion.
Bears say
Glaukos Corporation faces significant headwinds that adversely impact its financial outlook, primarily due to lower-than-expected growth in the minimally invasive glaucoma surgery (MIGS) market and a sluggish adoption of its iDose and iStent infinite products. The competitive landscape continues to intensify with an increasing number of entrants, coupled with potential reimbursement challenges, which may hinder sales execution and adoption rates across its product lines. Additionally, risks surrounding the timely realization of pipeline products and new launches further contribute to uncertainty in Glaukos' growth trajectory.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares